Treatment of hepatitis delta virus infection with interferon lambda
AssigneeEiger BioPharmaceuticals, Inc.
InventorEduardo Bruno MARTINS
Life of this patent
Estimating the term…
Abstract
Methods of treating a hepatitis delta virus (HDV) infection in a human patient are provided. In some embodiments, the method comprising administering to the patient a therapeutically effective amount of interferon lambda for at least four weeks.
Claims36
1-23. (canceled)
A method of treating a hepatitis delta virus (HDV) infection in a human patient, the method comprising:
- administering to the patient a therapeutically effective amount of interferon lambda for a first treatment period, wherein the interferon lambda is administered at a first dosage;
- and
- administering to the patient a therapeutically effective amount of interferon lambda for a second treatment period, wherein the interferon lambda is administered at a second dosage.
A method of treating a hepatitis delta virus (HDV) infection in a human patient, the method comprising administering to the patient a therapeutically effective amount of interferon lambda, wherein administration of the interferon lambda to the patient results in an initial increase in patient HDV viral load.
A method of treating a hepatitis delta virus (HDV) infection in a human patient, the method comprising administering to the patient a therapeutically effective amount of interferon lambda, wherein the patient exhibits one or more symptoms of liver dysfunction.
A method of treating a hepatitis delta virus (HDV) infection in a human patient, the method comprising:
- administering to the patient a therapeutically effective amount of interferon lambda, wherein the patient exhibits one or more symptoms of liver dysfunction;
- and
- assessing an improvement in liver fibrosis by conducting a biopsy and one or more of histological analysis, transient ultrasound elastography, and magnetic resonance elastography.
Dependencies are inferred from the claim text.